CStone Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 2.25 years. total yearly compensation is CN¥57.81M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 1.29% of the company’s shares, worth HK$33.88M. The average tenure of the management team and the board of directors is 2 years and 5.7 years respectively.

Belangrijke informatie

Jason Yang

Algemeen directeur

CN¥57.8m

Totale compensatie

Percentage CEO-salaris	8.3%
Dienstverband CEO	2.3yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	5.7yrs

Recente managementupdates

Recent updates

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

Oct 04

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

May 12

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Mar 04

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Jan 18

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Oct 04

Analyse CEO-vergoeding

Hoe is Jason Yang's beloning veranderd ten opzichte van CStone Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥142m
Mar 31 2024	n/a	n/a	-CN¥255m
Dec 31 2023	CN¥58m	CN¥5m	-CN¥367m
Sep 30 2023	n/a	n/a	-CN¥559m
Jun 30 2023	n/a	n/a	-CN¥750m
Mar 31 2023	n/a	n/a	-CN¥827m
Dec 31 2022	CN¥62m	CN¥3m	-CN¥903m

Compensatie versus markt: Jason's total compensation ($USD8.15M) is above average for companies of similar size in the Hong Kong market ($USD399.57K).

Compensatie versus inkomsten: Jason's compensation has been consistent with company performance over the past year.

CEO

Jason Yang (60 yo)

2.3yrs

Tenure

CN¥57,808,000

Compensatie

Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was its Senior Vice President and Chief Medical Officer December 2016 until 2024. He...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jianxin Yang	CEO, President of R&D and Executive Director	2.3yrs	CN¥57.81m	1.29% HK$ 34.7m
Weicong Ni	CFO & Joint Company Secretary	1.8yrs	geen gegevens	geen gegevens
Ying Hua Zhang	Senior VP & Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Ngai Chiu Tse	Senior VP & Chief Scientific Officer	no data	geen gegevens	geen gegevens
Michael J. Choi	Chief Commercial & Strategic Officer	3.5yrs	geen gegevens	geen gegevens
Yujuan La	Senior Vice President of Product Development	3.5yrs	geen gegevens	geen gegevens
Mei Yee Yung	Joint Company Secretary	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: 2616's management team is considered experienced (2 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jianxin Yang	CEO, President of R&D and Executive Director	no data	CN¥57.81m	1.29% HK$ 34.7m
Paul A. Bunn	Member of Scientific Advisory Board	5.7yrs	geen gegevens	geen gegevens
Hongbin Sun	Independent Non-Executive Director	5.8yrs	CN¥282.00k	geen gegevens
Xianghong Lin	Non-Executive Director	4yrs	geen gegevens	geen gegevens
Ting Yuk Wu	Independent Non-Executive Director	5.8yrs	CN¥711.00k	geen gegevens
Kenneth Walton Hitchner	Non Executive Director	2.9yrs	CN¥415.00k	geen gegevens
Weiping Zou	Member of Scientific Advisory Board	5.4yrs	geen gegevens	geen gegevens
Paul Herbert Chew	Independent Non-Executive Director	5.8yrs	CN¥282.00k	geen gegevens
Wei Li	Non-Executive Chairman	8.9yrs	geen gegevens	geen gegevens
Zhengguo Hu	Non-Executive Director	3.3yrs	geen gegevens	0.072% HK$ 1.9m

5.7yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: 2616's board of directors are considered experienced (5.7 years average tenure).

CStone Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Non-Executive Director recently bought HK$1.9m worth of stock

Key Executive recently bought HK$1.5m worth of stock

CStone Pharmaceuticals Announces Change of Joint Company Secretary

CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024

CEO, Senior VP & Chief Medical Officer recently bought HK$385k worth of stock

CEO, Senior VP & Chief Medical Officer recently bought HK$1.1m worth of stock

Recent updates

Non-Executive Director recently bought HK$1.9m worth of stock

CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

Key Executive recently bought HK$1.5m worth of stock

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

Consensus revenue estimates decrease by 38%, EPS upgraded

CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024

CStone Pharmaceuticals Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer

CStone Pharmaceuticals Announces Change of Joint Company Secretary

CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024

CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA

Forecast to breakeven in 2026

CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Consensus EPS estimates fall by 38%

New minor risk - Share price stability

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma

CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma

CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma

CEO, Senior VP & Chief Medical Officer recently bought HK$385k worth of stock

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application

CEO, Senior VP & Chief Medical Officer recently bought HK$1.1m worth of stock

CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023

CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer

CEO, Senior VP & Chief Medical Officer recently bought HK$676k worth of stock

CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023

CEO, Senior VP & Chief Medical Officer recently bought HK$285k worth of stock

CEO, Senior VP & Chief Medical Officer recently bought HK$457k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2024

No longer forecast to breakeven

CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million.

CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022

Cstone Pharmaceuticals Announces Management Changes

CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China

CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints

CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist

Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022

CEO, Senior VP & Chief Medical Officer recently bought HK$2.2m worth of stock

Less than half of directors are independent

Forecast to breakeven in 2024

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals

CEO, Senior VP & Chief Medical Officer recently bought HK$668k worth of stock

CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab

CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022

CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022

CStone Pharmaceuticals Announces Executive Changes

Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

Forecast to breakeven in 2024

CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022

CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022

CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022

CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022

Less than half of directors are independent

CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC

CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo

CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022

CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC